Sanofi's Future Brought Into Question By Elf Move

6 January 1997

French health and beauty company Sanofi has entered the mergers andacquisitions market in a move by the firm's parent company, Elf Aquitaine, which holds a 53% stake, valued at around 27 billion French francs ($5.1 billion).

In a statement relating to Elf's estimated 1996 net income, the petrochemicals firm said "it would be desirable for Sanofi to move nearer other pharmaceutical laboratories, through a merger, in order to speed up its development and increase its profitability."

Elf intends to remain "an important shareholder" for Sanofi but indicated that this does not mean that a major stake in the company is a prerequisite.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight